Ball Mark W, Hemal Ashok K, Allaf Mohamad E
James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Department of Urology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
BJU Int. 2017 Jan;119(1):13-21. doi: 10.1111/bju.13592. Epub 2016 Aug 19.
The aim of this study was to provide an evidence-based systematic review of the use of laparoscopic and robotic adrenalectomy in the treatment of adrenal disease as part of the International Consultation on Urological Diseases and European Association of Urology consultation on Minimally Invasive Surgery in Urology. A systematic literature search (January 2004 to January 2014) was conducted to identify comparative studies assessing the safety and efficacy of minimally invasive adrenal surgery. Subtopics including the role of minimally invasive surgery for pheochromocytoma, adrenocortical carcinoma (ACC) and large adrenal tumours were examined. Additionally, the role of transperitoneal and retroperitoneal approaches, as well as laparoendoscopic single-site (LESS) and robotic adrenalectomy were reviewed. The major findings are presented in an evidence-based fashion. Large retrospective and prospective data were analysed and a set of recommendations provided by the committee was produced. Laparoscopic surgery should be considered the first-line therapy for benign adrenal masses requiring surgical resection and for patients with pheochromocytoma. While a laparoscopic approach may be feasible for selected cases of ACC without adjacent organ involvement, an open surgical approach remains the 'gold standard'. Large adrenal tumours without preoperative or intra-operative suspicion of ACC may be safely resected via a laparoscopic approach. Both transperitoneal and retroperitoneal approaches to laparoscopic adrenalectomy are safe. The approach should be chosen based on surgeon training and experience. LESS and robotic adrenalectomy should be considered as alternatives to laparoscopic adrenalectomy but require further study.
本研究旨在作为国际泌尿疾病咨询委员会和欧洲泌尿外科学会泌尿外科微创手术咨询的一部分,对腹腔镜和机器人肾上腺切除术治疗肾上腺疾病进行循证系统评价。进行了系统的文献检索(2004年1月至2014年1月),以确定评估微创肾上腺手术安全性和有效性的比较研究。研究了包括微创手术在嗜铬细胞瘤、肾上腺皮质癌(ACC)和巨大肾上腺肿瘤治疗中的作用等子主题。此外,还回顾了经腹和腹膜后入路以及腹腔镜单孔手术(LESS)和机器人肾上腺切除术的作用。主要研究结果以循证方式呈现。分析了大量回顾性和前瞻性数据,并形成了委员会提出的一系列建议。对于需要手术切除的良性肾上腺肿块以及嗜铬细胞瘤患者,腹腔镜手术应被视为一线治疗方法。虽然对于某些未累及邻近器官的ACC病例,腹腔镜手术方法可能可行,但开放手术方法仍是“金标准”。对于术前或术中未怀疑为ACC的巨大肾上腺肿瘤,可通过腹腔镜手术安全切除。腹腔镜肾上腺切除术的经腹和腹膜后入路均安全。应根据外科医生的培训和经验选择手术入路。LESS和机器人肾上腺切除术应被视为腹腔镜肾上腺切除术的替代方法,但需要进一步研究。